EFFECTORBIO

pM-2.png
pM-2.png

press to zoom
468-SH+PAC-1'.png
468-SH+PAC-1'.png

press to zoom
IMG_6285.JPG
IMG_6285.JPG

press to zoom
pM-2.png
pM-2.png

press to zoom
 
162-1-1.png

OUR STORY

On the surface, we’re a dedicated group of scientists with a novel therapeutic that we hope will provide patients with a better tomorrow. Whether we’re at the lab running experiments or applying for grants, our startup has been operating since 2016, and this is just the beginning.

 

KEY PUBLICATIONS

UPREGULATION OF MARCKS IN KIDNEY CANCER AND ITS POTENTIAL AS A THERAPEUTIC TARGET

February 6, 2017

TARGETING MYRISTOYLATED ALANINE-RICH C KINASE SUBSTRATE PHOSPHORYLATION SITE DOMAIN IN LUNG CANCER. MECHANISMS AND THERAPEUTIC IMPLICATIONS

November 15, 2014

MARCKS IS MARKED IN COMBATING LUNG CANCER GROWTH AND ACQUIRED RESISTANCE

November 15, 2015

ELEVATED MARCKS PHOSPHORYLATION CONTRIBUTES TO UNRESPONSIVENESS OF BREAST CANCER TO PACLITAXEL TREATMENT

June 20, 2015

A PEPTIDE THAT INHIBITS FUNCTION OF MYRISTOYLATED ALANINE-RICH C KINASE SUBSTRATE (MARCKS) REDUCES LUNG CANCER METASTASIS

July 10, 2014

A NOVEL PREDICTOR OF CANCER MALIGNANCY: UP-REGULATION OF MYRISTOYLATED ALANINE-RICH C KINASE SUBSTRATE PHOSPHORYLATION IN LUNG CANCER

April 15, 2014

 
IMG_6313.JPG

New Horizons In Therapy

NOVEL THERAPIES FOR OLD PROBLEMS

At Effectorbio, translational medicine is at our core. We are focused on the therapeutics of tomorrow, and our main goal is bringing discoveries from the bench to bedside. The critical aspect of our company is to propel preclinical findings into clinical trials that will help build a better tomorrow for everyone.

 

FOR INVESTORS

 

GRANT AWARDS

Effectorbio Inc has been awarded multiple grants since 2016 and is currently pursuing support from the National Institutes of Health (NIH) small business grants.

IMG_6321.JPG

THERAPEUTIC POTENTIAL

We have developed a novel 25-mer therapeutic peptide drug targeting the MARCKS Phosphorylation Site domain (MPS). Studies have shown promising results in suppressing multiple human diseases including but not limited to cancer, asthma, and pulmonary fibrosis.

structure of orthotopic paper.jpg

INVESTMENT OPPORTUNITIES

Currently, the company is supported by various grants from both domestic and abroad. We are looking for partners interested in developing novel therapeutics in the areas of cancer and inflammatory pulmonary diseases.

IMG_2219.JPG

GET IN TOUCH

Thanks for submitting!

  • Facebook
  • Twitter
  • LinkedIn